Jove
Visualize
Contact Us

Related Experiment Videos

The hypercoagulability of polycythemia vera

W Fields1, N J Freeman

  • 1Brown University.

Hospital Practice (Office Ed.)
|September 30, 1993
PubMed
Summary

Thrombosis, a leading cause of death in myeloproliferative neoplasms, remains a significant challenge. Current treatments like phlebotomy and hydroxyurea may not fully prevent fatal blood clots.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher sociability leads to lower reproductive success in female kangaroos.

Royal Society open science·2020
Same author

An inter-machine comparison of tobacco smoke particle deposition in vitro from six independent smoke exposure systems.

Toxicology in vitro : an international journal published in association with BIBRA·2014
Same author

Evidence for scent marking in vervet monkeys?

Primates; journal of primatology·2012
Same author

Measurement of conformational changes in the structure of transglutaminase on binding calcium ions using optical evanescent dual polarisation interferometry.

Analytical chemistry·2007
Same author

Quantifying the effects of melittin on liposomes.

Biochimica et biophysica acta·2006
Same author

Lessons learned during 15 years of clinical information system experience.

Computers in nursing·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Hematology
  • Oncology
  • Vascular Medicine

Background:

  • Thrombosis is the primary cause of mortality in patients diagnosed with myeloproliferative neoplasms.
  • Existing therapeutic strategies include phlebotomy, hydroxyurea, and antiplatelet agents.
  • These treatments may be insufficient in preventing life-threatening embolic events.